Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto
Publicado
Dec 18, 2018
Almetrics
Dimensions
Google Scholar
##plugins.themes.bootstrap3.article.details##
Resumo
Los tumores primarios del sistema nervioso representaron aproximadamente el 1,4 % de los nuevos diagnósticos de cáncer en 2015 y causan el 2,6 % de las muertes por cáncer. Estos tienen una mayor implicación clínica en la población infantil y en adultos jóvenes; y su incidencia disminuye con la edad. Los tumores más frecuentes en los adultos incluyen meningiomas, gliomas y tumores pituitarios. En este artículo se hace una revisión actualizada sobre la epidemiología de los tumores primarios del sistema nervioso, así como las principales características y actualizaciones en el manejo de los tumores más prevalentes en la población adulta.
Keywords
References
1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18:v1-75.
2. McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981-98.
3. Coebergh JW, Van Den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015;51(9):1050-63.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
5. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex. 2016;58(2):104-17.
6. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016;135:253-74.
7. Pardo, C. Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007-2011. Vol. 1. Bogotá: Instituto Nacional de Cancerologia; 2015.
8. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2011 Jan;15(3):127-34.
9. Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2014;Epub:pii: S0028-3770(14)00112-X.
10. Fathi A-R, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013 Apr;13(4):337.
11. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
12. Evans DGR. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87-96.
13. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86.
14. Igaz P. MEN1 clinical background. Adv Exp Med Biol. 2009;668:1-15.
15. Alegre M, Puig L, de Moragas JM. The Gorlin syndrome. A review of 11 cases. Rev Clin Esp. 1995 Oct;195(10):684-7.
16. Watkins D, Rouleau GA. Genetics, prognosis and therapy of central nervous system tumors. Cancer Detect Prev. 1994;18(2):139-44.
17. Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: Review and recommendations for current practice. Am J Neuroradiol. 2012;33(5):803-17.
18. Bellail AC, Olson JJ, Hao C. Current Brain Tumor Imaging. 2014;81(3):397-415.
19. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006 Nov;98(21):1528-37.
20. Rapalino O, Smirniotopoulos JG. Extra-axial brain tumors. Handb Clin Neurol. 2016;135:275-91. doi: https://doi.org/10.1016/B978-0-444-53485-9.00015-5.
21. Hortobágyi T, Bencze J, Varkoly G, Kouhsari MC, Klekner Á. Meningioma recurrence. Open Med. 2016 Jan;11(1):168-73. doi: https://doi.org/10.1515/med-2016-0032.
22. Pinzi V, Biagioli E, Roberto A, Galli F, Rizzi M, Chiappa F, et al. Radiosurgery for intracranial meningiomas: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 May;113:122-34.
23. Kaul D, Budach V, Wurm R, Gruen A, Graaf L, Habbel P, et al. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiat Oncol. 2014;9(1):78.
24. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May;9(3):231-40.
25. Cohen-Inbar O, Lee C, Sheehan JP. The contemporary role of stereotactic radiosurgery in the treatment of meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):215-28.
26. Buttrick S, Shah AH, Komotar RJ, Ivan ME. Management of atypical and anaplastic meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):239-47.
27. Spasic M, Pelargos PE, Barnette N, Bhatt NS, Lee SJ, Ung N, et al. Incidental Meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):229-38.
28. Bi WL, Dunn IF. Current and emerging principles in surgery for meningioma. Chinese Clin Oncol [Internet]. 2017;6(S1):S7. Disponible en: http://cco.amegroups.com/article/view/15463/15715.
29. Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44(4):E3. doi: https://doi.org/10.3171/2018.1.FOCUS17754.
30. Robin AM, Lee I, Kalkanis SN. Reoperation for Recurrent Glioblastoma Multiforme. Neurosurg Clin N Am. 2017;28(3):407-28.
31. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 2017;8:99-113.
32. Noorani I, Sanai N. Surgical management of incidental gliomas. Neurosurg Clin N Am. 2017;28(3):397-406.
33. Stupp R, Mason W, Bent M van den, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for globlastoma. N Engl J Med. 2005;352:987-96.
34. Sociedad Española de Neurorradiología. Criterios de respuesta de los tumores cerebrales. Soc Española Neurorradiología [Internet]. 2011;1-16. Disponible en: http://www.senr.org/pdf/section_5/Criterios_respuesta_Tumores_Cerebrales.pdf.
35. Morshed RA, Young JS, Hervey-Jumper SL. Sharpening the surgeon's knife: Value of extent of resection for glioma in the molecular age. World Neurosurg. 2018 Jul 5;117:350-2. doi: http://dx.doi.org/10.1016/j.wneu.2018.06.149.
36. Stepp H, Stummer W. 5-ALA in the management of malignant glioma. Lasers Surg Med. 2018;(April). doi: http://doi.wiley.com/10.1002/lsm.22933 %0A.
37. Šteňo A, Jezberová M, Hollý V, Timárová G, Šteňo J. Visualization of lenticulostriate arteries during insular low-grade glioma surgeries by navigated 3D ultrasound power Doppler: technical note. J Neurosurg. 2016;125(4):1016-23. doi: http://thejns.org/doi/10.3171/2015.10.JNS151907.
38. Moiyadi AV, Shetty PM, Mahajan A, Udare A, Sridhar E. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien). 2013;155(12):2217-25.
39. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017 Oct;134(4):521-35.
40. Greenman Y. Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol. 2017 Sep;177(3):R113-24.
41. Zhang Y, Wang Z, Liu Y, Zong X, Song M, Pei A, et al. Endoscopic transsphenoidal treatment of pituitary adenomas. Neurol Res. 2008;30(6):581-6.
42. Kassam AB, Prevedello DM, Carrau RL, Snyderman CH, Thomas A, Gardner P, et al. Endoscopic endonasal skull base surgery: analysis of complications in the authors’ initial 800 patients. J Neurosurg. 2011;114(6):1544-68.
43. Cavallo LM, Solari D, Tasiou A, Esposito F, De Angelis M, D’Enza AI, et al. Endoscopic endonasal transsphenoidal removal of recurrent and regrowing pituitary adenomas: Experience on a 59-patient series. World Neurosurg. 2013;80(3-4):342-50. doi: https://doi.org/10.1016/j.wneu.2012.10.008
44. Kalinin PL, Kadashev BA, Fomichev D V, Kutin MA, Astaf’eva LI, Sharipov OI, et al. [Surgical treatment for pituitary adenomas]. Zh Vopr Neirokhir Im N N Burdenko. 81(1):95-107.
45. Rogers A, Karavitaki N, Wass JAH. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014 Sep;349:g5390.
46. Molitch ME. Nonfunctioning pituitary tumors. Handb Clin Neurol. 2014;124:167-84. doi: https://doi.org/10.1016/B978-0-444-59602-4.00012-5.
47. Tampourlou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne J V., et al. Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: A study from two large UK centers. J Clin Endocrinol Metab. 2017 Jun;102(6):1889-97.
48. Greenman Y, Stern N. Optimal management of non-functioning pituitary adenomas. Endocrine. 2015 Sep;50(1):51-5.
49. Langlois F, Mccartney S, Fleseriu M. Recent progress in the medical therapy of pituitary tumors. Endocrinol Metab [Internet]. 2017;32(2):162-70. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503860/pdf/enm-32-162.pdf
50. Cohen-Inbar O. [Radiosurgery for pituitary adenomas]. Harefuah. 2017 Jan;156(1):45-50.
51. Shore RE, Moseson M, Harley N, Pasternack BS. Tumors and other diseases following childhood x-ray treatment for ringworm of the scalp (Tinea capitis). Health Phys. 2003 Oct;85(4):404-8.
52. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2010 Dec;28(36):5287-93.
53. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children’s Research Hospital. J Clin Oncol. 1998 Dec;16(12):3761-7.
54. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012 Nov;14(11):1316-24.
55. Interphone Study Group. Brain tumour risk in relation to mobile telephone use: results of the Interphone international case-control study. Int J Epidemiol. 2010 Jun;39(3):675-94.
56. Brossier NM, Gutmann DH. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015 Apr;15(4):415-23.
57. Maldonado ICM, Contreras LL, García AN, Quintana OB, Rodríguez JA. Clasificación morfológica de meningiomas en una casuística del Hospital Universitario Dr. José E González. Patología (Mex). 2011;49(3):188-95.
58. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383-91. doi: http://dx.doi.org/10.1016/S1470-2045(16)30321-7.
2. McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981-98.
3. Coebergh JW, Van Den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, et al. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015;51(9):1050-63.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
5. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex. 2016;58(2):104-17.
6. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016;135:253-74.
7. Pardo, C. Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007-2011. Vol. 1. Bogotá: Instituto Nacional de Cancerologia; 2015.
8. Suárez A, Castellanos M, Simbaqueba A, Gamboa Ó. Aspectos clínicos y demora para el diagnóstico en niños con tumores del sistema nervioso central en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2011 Jan;15(3):127-34.
9. Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. Neurochirurgie. 2014;Epub:pii: S0028-3770(14)00112-X.
10. Fathi A-R, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013 Apr;13(4):337.
11. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
12. Evans DGR. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87-96.
13. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86.
14. Igaz P. MEN1 clinical background. Adv Exp Med Biol. 2009;668:1-15.
15. Alegre M, Puig L, de Moragas JM. The Gorlin syndrome. A review of 11 cases. Rev Clin Esp. 1995 Oct;195(10):684-7.
16. Watkins D, Rouleau GA. Genetics, prognosis and therapy of central nervous system tumors. Cancer Detect Prev. 1994;18(2):139-44.
17. Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: Review and recommendations for current practice. Am J Neuroradiol. 2012;33(5):803-17.
18. Bellail AC, Olson JJ, Hao C. Current Brain Tumor Imaging. 2014;81(3):397-415.
19. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006 Nov;98(21):1528-37.
20. Rapalino O, Smirniotopoulos JG. Extra-axial brain tumors. Handb Clin Neurol. 2016;135:275-91. doi: https://doi.org/10.1016/B978-0-444-53485-9.00015-5.
21. Hortobágyi T, Bencze J, Varkoly G, Kouhsari MC, Klekner Á. Meningioma recurrence. Open Med. 2016 Jan;11(1):168-73. doi: https://doi.org/10.1515/med-2016-0032.
22. Pinzi V, Biagioli E, Roberto A, Galli F, Rizzi M, Chiappa F, et al. Radiosurgery for intracranial meningiomas: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 May;113:122-34.
23. Kaul D, Budach V, Wurm R, Gruen A, Graaf L, Habbel P, et al. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiat Oncol. 2014;9(1):78.
24. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May;9(3):231-40.
25. Cohen-Inbar O, Lee C, Sheehan JP. The contemporary role of stereotactic radiosurgery in the treatment of meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):215-28.
26. Buttrick S, Shah AH, Komotar RJ, Ivan ME. Management of atypical and anaplastic meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):239-47.
27. Spasic M, Pelargos PE, Barnette N, Bhatt NS, Lee SJ, Ung N, et al. Incidental Meningiomas. Neurosurg Clin N Am. 2016 Apr;27(2):229-38.
28. Bi WL, Dunn IF. Current and emerging principles in surgery for meningioma. Chinese Clin Oncol [Internet]. 2017;6(S1):S7. Disponible en: http://cco.amegroups.com/article/view/15463/15715.
29. Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44(4):E3. doi: https://doi.org/10.3171/2018.1.FOCUS17754.
30. Robin AM, Lee I, Kalkanis SN. Reoperation for Recurrent Glioblastoma Multiforme. Neurosurg Clin N Am. 2017;28(3):407-28.
31. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 2017;8:99-113.
32. Noorani I, Sanai N. Surgical management of incidental gliomas. Neurosurg Clin N Am. 2017;28(3):397-406.
33. Stupp R, Mason W, Bent M van den, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for globlastoma. N Engl J Med. 2005;352:987-96.
34. Sociedad Española de Neurorradiología. Criterios de respuesta de los tumores cerebrales. Soc Española Neurorradiología [Internet]. 2011;1-16. Disponible en: http://www.senr.org/pdf/section_5/Criterios_respuesta_Tumores_Cerebrales.pdf.
35. Morshed RA, Young JS, Hervey-Jumper SL. Sharpening the surgeon's knife: Value of extent of resection for glioma in the molecular age. World Neurosurg. 2018 Jul 5;117:350-2. doi: http://dx.doi.org/10.1016/j.wneu.2018.06.149.
36. Stepp H, Stummer W. 5-ALA in the management of malignant glioma. Lasers Surg Med. 2018;(April). doi: http://doi.wiley.com/10.1002/lsm.22933 %0A.
37. Šteňo A, Jezberová M, Hollý V, Timárová G, Šteňo J. Visualization of lenticulostriate arteries during insular low-grade glioma surgeries by navigated 3D ultrasound power Doppler: technical note. J Neurosurg. 2016;125(4):1016-23. doi: http://thejns.org/doi/10.3171/2015.10.JNS151907.
38. Moiyadi AV, Shetty PM, Mahajan A, Udare A, Sridhar E. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien). 2013;155(12):2217-25.
39. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017 Oct;134(4):521-35.
40. Greenman Y. Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol. 2017 Sep;177(3):R113-24.
41. Zhang Y, Wang Z, Liu Y, Zong X, Song M, Pei A, et al. Endoscopic transsphenoidal treatment of pituitary adenomas. Neurol Res. 2008;30(6):581-6.
42. Kassam AB, Prevedello DM, Carrau RL, Snyderman CH, Thomas A, Gardner P, et al. Endoscopic endonasal skull base surgery: analysis of complications in the authors’ initial 800 patients. J Neurosurg. 2011;114(6):1544-68.
43. Cavallo LM, Solari D, Tasiou A, Esposito F, De Angelis M, D’Enza AI, et al. Endoscopic endonasal transsphenoidal removal of recurrent and regrowing pituitary adenomas: Experience on a 59-patient series. World Neurosurg. 2013;80(3-4):342-50. doi: https://doi.org/10.1016/j.wneu.2012.10.008
44. Kalinin PL, Kadashev BA, Fomichev D V, Kutin MA, Astaf’eva LI, Sharipov OI, et al. [Surgical treatment for pituitary adenomas]. Zh Vopr Neirokhir Im N N Burdenko. 81(1):95-107.
45. Rogers A, Karavitaki N, Wass JAH. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014 Sep;349:g5390.
46. Molitch ME. Nonfunctioning pituitary tumors. Handb Clin Neurol. 2014;124:167-84. doi: https://doi.org/10.1016/B978-0-444-59602-4.00012-5.
47. Tampourlou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne J V., et al. Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: A study from two large UK centers. J Clin Endocrinol Metab. 2017 Jun;102(6):1889-97.
48. Greenman Y, Stern N. Optimal management of non-functioning pituitary adenomas. Endocrine. 2015 Sep;50(1):51-5.
49. Langlois F, Mccartney S, Fleseriu M. Recent progress in the medical therapy of pituitary tumors. Endocrinol Metab [Internet]. 2017;32(2):162-70. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503860/pdf/enm-32-162.pdf
50. Cohen-Inbar O. [Radiosurgery for pituitary adenomas]. Harefuah. 2017 Jan;156(1):45-50.
51. Shore RE, Moseson M, Harley N, Pasternack BS. Tumors and other diseases following childhood x-ray treatment for ringworm of the scalp (Tinea capitis). Health Phys. 2003 Oct;85(4):404-8.
52. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol. 2010 Dec;28(36):5287-93.
53. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children’s Research Hospital. J Clin Oncol. 1998 Dec;16(12):3761-7.
54. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012 Nov;14(11):1316-24.
55. Interphone Study Group. Brain tumour risk in relation to mobile telephone use: results of the Interphone international case-control study. Int J Epidemiol. 2010 Jun;39(3):675-94.
56. Brossier NM, Gutmann DH. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015 Apr;15(4):415-23.
57. Maldonado ICM, Contreras LL, García AN, Quintana OB, Rodríguez JA. Clasificación morfológica de meningiomas en una casuística del Hospital Universitario Dr. José E González. Patología (Mex). 2011;49(3):188-95.
58. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383-91. doi: http://dx.doi.org/10.1016/S1470-2045(16)30321-7.
Como Citar
Ocampo Navia, M. I., Gómez Vega, J. C., & Feo Lee, O. H. (2018). Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto. Universitas Medica, 60(1). https://doi.org/10.11144/Javeriana.umed60-1.cere
Edição
Seção
Artículos de revisión